Evana

Evana is an over-the-counter (OTC) formulation of tranexamic acid (500 mg) developed by Maxwellia, a UK-based consumer healthcare company. It is specifically indicated for the reduction of heavy menstrual bleeding in women with regular menstrual cycles. As an antifibrinolytic agent, tranexamic acid works by competitively inhibiting the activation of plasminogen to plasmin. By binding to the lysine-binding sites on plasminogen molecules, it prevents the degradation of fibrin, thereby stabilizing blood clots and reducing menstrual blood loss by up to 60%. Evana represents a significant Rx-to-OTC switch, making this treatment available without a prescription for the first time in the UK.

Brand names

Evana

Other names

tranexamic acid 500 mg